Implications for the Kynurenine Pathway and Quinolinic Acid in Amyotrophic Lateral Sclerosis
暂无分享,去创建一个
[1] W. Bradley,et al. Mitochondrial involvement in amyotrophic lateral sclerosis , 2007, Molecular Neurobiology.
[2] V. Meininger. Clinical Trials in ALS: What Did We Learn from Recent Trials in Humans? , 2006, Neurodegenerative Diseases.
[3] D. Walker,et al. Quinolinic acid promotes albumin deposition in Purkinje cell, astrocytic activation and lipid peroxidation in fetal brain , 2005, Neuroscience.
[4] P. Monk,et al. Microglia as potential contributors to motor neuron injury in amyotrophic lateral sclerosis , 2005, Glia.
[5] B. Brew,et al. Indoleamine 2,3 dioxygenase and quinolinic acid Immunoreactivity in Alzheimer's disease hippocampus , 2005, Neuropathology and applied neurobiology.
[6] B. Brew,et al. Quinolinic acid selectively induces apoptosis of human astrocytes: potential role in AIDS dementia complex , 2005, Journal of Neuroinflammation.
[7] T. Möller,et al. Neuroinflammation in the pathogenesis of amyotrophic lateral sclerosis , 2005, Neuroreport.
[8] B. Brew,et al. Expression of indoleamine 2,3‐dioxygenase and production of quinolinic acid by human microglia, astrocytes, and neurons , 2005, Glia.
[9] A. Cesura,et al. Expression of the kynurenine enzymes in macrophages and microglial cells: regulation by immune modulators , 2005, Amino Acids.
[10] I. Lapin,et al. Excitatory effects of kynurenine and its metabolites, amino acids and convulsants administered into brain ventricles: Differences between rats and mice , 2005, Journal of Neural Transmission.
[11] S. Appel,et al. Sublethal dose of 4-hydroxynonenal reduces intracellular calcium in surviving motor neurons in vivo , 2005, Acta Neuropathologica.
[12] J. Joseph,et al. Mass spectral evidence for carbonate-anion-radical-induced posttranslational modification of tryptophan to kynurenine in human Cu, Zn superoxide dismutase. , 2004, Free radical biology & medicine.
[13] J. Reinhard. Pharmacological Manipulation of Brain Kynurenine Metabolism , 2004, Annals of the New York Academy of Sciences.
[14] L. Barbeito,et al. A role for astrocytes in motor neuron loss in amyotrophic lateral sclerosis , 2004, Brain Research Reviews.
[15] T. Gillingwater,et al. A mutation in the vesicle-trafficking protein VAPB causes late-onset spinal muscular atrophy and amyotrophic lateral sclerosis. , 2004, American journal of human genetics.
[16] W. Le,et al. Activated Microglia Initiate Motor Neuron Injury by a Nitric Oxide and Glutamate‐Mediated Mechanism , 2004, Journal of neuropathology and experimental neurology.
[17] J. Loeffler,et al. Evidence for defective energy homeostasis in amyotrophic lateral sclerosis: benefit of a high-energy diet in a transgenic mouse model. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[18] H. Shibasaki,et al. Effects of mitochondrial dysfunction on glutamate receptor-mediated neurotoxicity in cultured rat spinal motor neurons , 2004, Brain Research.
[19] Deanna L. Taylor,et al. Microglia release activators of neuronal proliferation mediated by activation of mitogen‐activated protein kinase, phosphatidylinositol‐3‐kinase/Akt and delta–Notch signalling cascades , 2004, Journal of neurochemistry.
[20] L. Bruijn,et al. Unraveling the mechanisms involved in motor neuron degeneration in ALS. , 2004, Annual review of neuroscience.
[21] S. Paredes,et al. Orally administered tryptophan and experimental type 2 diabetes , 2004, Molecular and Cellular Biochemistry.
[22] U. Kumar. Characterization of striatal cultures with the effect of QUIN and NMDA , 2004, Neuroscience Research.
[23] A. Chakrabartty,et al. Monomeric Cu,Zn-superoxide Dismutase Is a Common Misfolding Intermediate in the Oxidation Models of Sporadic and Familial Amyotrophic Lateral Sclerosis*[boxs] , 2004, Journal of Biological Chemistry.
[24] L. Barbeito,et al. Astrocytic production of nerve growth factor in motor neuron apoptosis: implications for amyotrophic lateral sclerosis , 2004, Journal of neurochemistry.
[25] Colin L. Masters,et al. Neurodegenerative diseases and oxidative stress , 2004, Nature Reviews Drug Discovery.
[26] M. E. Frizzo,et al. Riluzole Enhances Glutamate Uptake in Rat Astrocyte Cultures , 2004, Cellular and Molecular Neurobiology.
[27] T. Siddique,et al. Presence of dendritic cells, MCP‐1, and activated microglia/macrophages in amyotrophic lateral sclerosis spinal cord tissue , 2004, Annals of neurology.
[28] S. Przedborski. Programmed Cell Death in Amyotrophic Lateral Sclerosis: a Mechanism of Pathogenic and Therapeutic Importance , 2004, The neurologist.
[29] H. Vinters,et al. Inflammation in amyotrophic lateral sclerosis spinal cord and brain is mediated by activated macrophages, mast cells and T cells , 2004, Amyotrophic lateral sclerosis and other motor neuron disorders : official publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases.
[30] A. Santamaría,et al. Quinolinic acid is a potent lipid peroxidant in rat brain homogenates , 1991, Neurochemical Research.
[31] I. Niebroj-Dobosz,et al. Oxidative damage to proteins in the spinal cord in amyotrophic lateral sclerosis (ALS). , 2004, Folia neuropathologica.
[32] G. Deuschl,et al. Intrathecal synthesis of monocyte chemoattractant protein-1 (MCP-1) in amyotrophic lateral sclerosis: further evidence for microglial activation in neurodegeneration , 2003, Journal of Neuroimmunology.
[33] Scott Ferrell,et al. Message and protein-level elevation of tumor necrosis factor α (TNFα) and TNFα-modulating cytokines in spinal cords of the G93A-SOD1 mouse model for amyotrophic lateral sclerosis , 2003, Neurobiology of Disease.
[34] M. Strong,et al. Amyotrophic lateral sclerosis: A review of current concepts , 2003, Amyotrophic lateral sclerosis and other motor neuron disorders : official publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases.
[35] J. Moffett,et al. Tryptophan and the immune response , 2003, Immunology and cell biology.
[36] K. Žarković. 4-hydroxynonenal and neurodegenerative diseases. , 2003, Molecular aspects of medicine.
[37] J. Joseph,et al. Bicarbonate-dependent Peroxidase Activity of Human Cu,Zn-Superoxide Dismutase Induces Covalent Aggregation of Protein , 2003, Journal of Biological Chemistry.
[38] W. Turski,et al. Endogenous protectant kynurenic acid in amyotrophic lateral sclerosis , 2003, Acta neurologica Scandinavica.
[39] B. Brew,et al. Expression of chemokines and their receptors in human and simian astrocytes: Evidence for a central role of TNFα and IFNγ in CXCR4 and CCR5 modulation , 2003 .
[40] B. Brew,et al. Quinolinic acid upregulates chemokine production and chemokine receptor expression in astrocytes , 2003, Glia.
[41] I. Regidor,et al. Low concentrations of glutamate induce apoptosis in cultured neurons: Implications for amyotrophic lateral sclerosis , 2003, Journal of the Neurological Sciences.
[42] S. Appel,et al. PARP Expression Is Increased in Astrocytes but Decreased in Motor Neurons in the Spinal Cord of Sporadic ALS Patients , 2003, Journal of neuropathology and experimental neurology.
[43] B. Brew,et al. Quinolinic acid in the pathogenesis of Alzheimer's disease. , 2003, Advances in experimental medicine and biology.
[44] B. Brew,et al. Expression of the kynurenine pathway enzymes in human microglia and macrophages. , 2003, Advances in experimental medicine and biology.
[45] W. Streit. Microglia as neuroprotective, immunocompetent cells of the CNS , 2002, Glia.
[46] P. Mcgeer,et al. Inflammatory processes in amyotrophic lateral sclerosis , 2002, Muscle & nerve.
[47] P. Heath,et al. Update on the glutamatergic neurotransmitter system and the role of excitotoxicity in amyotrophic lateral sclerosis , 2002, Muscle & nerve.
[48] K. Ikeda,et al. Molecular and cellular mechanism of glutamate receptors in relation to amyotrophic lateral sclerosis. , 2002, Current drug targets. CNS and neurological disorders.
[49] P. Riederer,et al. Degeneration of neuronal cells due to oxidative stress--microglial contribution. , 2002, Parkinsonism & related disorders.
[50] M. Strong,et al. Activated microglia (BV-2) facilitation of TNF-α-mediated motor neuron death in vitro , 2002, Journal of Neuroimmunology.
[51] A. Nagai,et al. Cytokines, chemokines, and cytokine receptors in human microglia , 2002, Journal of neuroscience research.
[52] K. Fischbeck,et al. Toxic Proteins in Neurodegenerative Disease , 2002, Science.
[53] D. Souza,et al. Quinolinic acid stimulates synaptosomal glutamate release and inhibits glutamate uptake into astrocytes , 2002, Neurochemistry International.
[54] P. Smyth,et al. Markers of apoptosis: methods for elucidating the mechanism of apoptotic cell death from the nervous system. , 2002, BioTechniques.
[55] V. Meininger,et al. Glutamate levels in cerebrospinal fluid in amyotrophic lateral sclerosis: a reappraisal using a new HPLC method with coulometric detection in a large cohort of patients , 2002, Journal of the Neurological Sciences.
[56] B Balachandran,et al. Role of Oxidative Stress and Antioxidants in Neurodegenerative Diseases , 2002, Nutritional neuroscience.
[57] K. Hensley,et al. Temporal patterns of cytokine and apoptosis-related gene expression in spinal cords of the G93A-SOD1 mouse model of amyotrophic lateral sclerosis. , 2002, Journal of neurochemistry.
[58] D. Price,et al. Histological Evidence of Protein Aggregation in Mutant SOD1 Transgenic Mice and in Amyotrophic Lateral Sclerosis Neural Tissues , 2001, Neurobiology of Disease.
[59] S Cluskey,et al. Mechanisms of neurodegeneration in amyotrophic lateral sclerosis , 2001, Molecular pathology : MP.
[60] B. Sela. [Role of caspases in neural degeneration in amyotrophic lateral sclerosis]. , 2001, Harefuah.
[61] N. Shibata,et al. Morphological evidence for lipid peroxidation and protein glycoxidation in spinal cords from sporadic amyotrophic lateral sclerosis patients , 2001, Brain Research.
[62] V. Silani,et al. Early vacuolization and mitochondrial damage in motor neurons of FALS mice are not associated with apoptosis or with changes in cytochrome oxidase histochemical reactivity , 2001, Journal of the Neurological Sciences.
[63] S. Appel,et al. Immune reactivity in a mouse model of familial ALS correlates with disease progression , 2001, Neurology.
[64] M. Swash,et al. Amyotrophic Lateral Sclerosis: Current Understanding , 2001, The Journal of neuroscience nursing : journal of the American Association of Neuroscience Nurses.
[65] A. Camacho,et al. In vivo hydroxyl radical formation after quinolinic acid infusion into rat corpus striatum , 2001, Neuroreport.
[66] B. Brew,et al. Kynurenine pathway metabolism in human astrocytes: a paradox for neuronal protection , 2001, Journal of neurochemistry.
[67] P. Ince,et al. Apoptosis in amyotrophic lateral sclerosis: a review of the evidence , 2001, Neuropathology and applied neurobiology.
[68] A. Santamaría,et al. Quinolinic acid induces oxidative stress in rat brain synaptosomes , 2001, Neuroreport.
[69] T. Stone,et al. Endogenous neurotoxins from tryptophan. , 2001, Toxicon : official journal of the International Society on Toxinology.
[70] M. Sanjak,et al. Mosaic chemotherapy strategies for developing ALS/MND therapeutic approaches: Beta-2 adrenergic agonists , 2000, Amyotrophic lateral sclerosis and other motor neuron disorders : official publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases.
[71] M. Müller,et al. Multidrug resistance protein MRP1 protects against the toxicity of the major lipid peroxidation product 4-hydroxynonenal. , 2000, The Biochemical journal.
[72] J. Urenjak,et al. NEUROPHARMACOLOGY: Neuroprotective potency of kynurenic acid against excitotoxicity , 2022 .
[73] D. Souza,et al. Quinolinic acid inhibits glutamate uptake into synaptic vesicles from rat brain , 2000, Neuroreport.
[74] W. Behan,et al. Possible mediation of quinolinic acid-induced hippocampal damage by reactive oxygen species , 2000, Amino Acids.
[75] T. Stone,et al. Oxidative stress as a mechanism for quinolinic acid‐induced hippocampal damage: protection by melatonin and deprenyl , 1999, British journal of pharmacology.
[76] R. Schwarcz,et al. 3‐Hydroxykynurenine potentiates quinolinate but not NMDA toxicity in the rat striatum , 1999, The European journal of neuroscience.
[77] D. Schiffer,et al. Lack of apoptosis in mice with ALS , 1999, Nature Medicine.
[78] F. Moroni,et al. Tryptophan metabolism and brain function: focus on kynurenine and other indole metabolites. , 1999, European journal of pharmacology.
[79] E. Fedele,et al. Intracerebral administration of l-kynurenine decreases N-methyl-d-aspartate receptor-mediated production of cGMP in the cerebellum and hippocampus of unanaesthetized rats subjected to transcerebral microdialysis , 1999, Neuroscience Letters.
[80] F. Moroni,et al. Neuroprotective effects of kynurenine-3-hydroxylase inhibitors in models of brain ischemia. , 1999, Advances in experimental medicine and biology.
[81] R. Stocker,et al. Redox reactions related to indoleamine 2,3-dioxygenase and tryptophan metabolism along the kynurenine pathway. , 1999, Redox report : communications in free radical research.
[82] M. Mattson,et al. Presence of 4‐hydroxynonenal in cerebrospinal fluid of patients with sporadic amyotrophic lateral sclerosis , 1998, Annals of neurology.
[83] L. Bruijn,et al. Aggregation and motor neuron toxicity of an ALS-linked SOD1 mutant independent from wild-type SOD1. , 1998, Science.
[84] Marco Di Benedetto,et al. Solution structure of reduced monomeric Q133M2 copper, zinc superoxide dismutase (SOD). Why is SOD a dimeric enzyme?. , 1998, Biochemistry.
[85] G. Wolf,et al. Differential expression of superoxide dismutase isoforms in neuronal and glial compartments in the course of excitotoxically mediated neurodegeneration: Relation to oxidative and nitrergic stress , 1998, Glia.
[86] A. Berger. Amyloid clearly implicated in Alzheimer's disease , 1998 .
[87] M. Gurney,et al. Relationship of oxygen radical‐induced lipid peroxidative damage to disease onset and progression in a transgenic model of familial ALS , 1998, Journal of neuroscience research.
[88] Bruce A. Yankner,et al. Aging renders the brain vulnerable to amyloid β-protein neurotoxicity , 1998, Nature Medicine.
[89] M. Sawada,et al. Tryptophan and its metabolite, kynurenine, stimulate expression of nerve growth factor in cultured mouse astroglial cells , 1998, Neuroscience Letters.
[90] B. Brew,et al. Chronic exposure of human neurons to quinolinic acid results in neuronal changes consistent with AIDS dementia complex , 1998, AIDS.
[91] B. Crain,et al. Linkage of the gene for an autosomal dominant form of juvenile amyotrophic lateral sclerosis to chromosome 9q34. , 1998, American journal of human genetics.
[92] G. Levi,et al. Microglia as effector cells in brain damage and repair: focus on prostanoids and nitric oxide , 1998, Progress in Neurobiology.
[93] A. Santamaría,et al. Effects of Nω-nitro-L-arginine and L-arginine on quinolinic acid-induced lipid peroxidation , 1997 .
[94] D. Troost,et al. c‐Jun, JNK/SAPK Kinase and Transcription Factor NF-κB Are Selectively Activated in Astrocytes, but not Motor Neurons, in Amyotrophic Lateral Sclerosis , 1997, Journal of neuropathology and experimental neurology.
[95] S. Furukawa,et al. Stimulation of NGF production by tryptophan and its metabolites in cultured mouse astroglial cells. , 1997, Brain research.
[96] B. Brew,et al. Quinolinic Acid Production by Macrophages Stimulated with IFN-γ, TNF-α, and IFN-α , 1997 .
[97] Dennis P. Nelson,et al. Energetic Dysfunction in Quinolinic Acid‐Lesioned Rat Striatum , 1997, Journal of neurochemistry.
[98] K. Kawai,et al. Species Heterogeneity Between Gerbils and Rats: Quinolinate Production by Microglia and Astrocytes and Accumulations in Response to Ischemic Brain Injury and Systemic Immune Activation , 1997, Journal of neurochemistry.
[99] Hassan Mohammad Naif,et al. HIV infection of macrophages and pathogenesis of AIDS dementia complex: interaction of the host cell and viral genotype , 1997, Journal of leukocyte biology.
[100] C. Colton,et al. Activated human microglia produce the excitotoxin quinolinic acid , 1997, Neuroreport.
[101] B. Brew,et al. Quinolinic acid production by macrophages stimulated with IFN-gamma, TNF-alpha, and IFN-alpha. , 1997, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.
[102] R. Stocker,et al. 3-Hydroxyanthranilic Acid Is an Efficient, Cell-derived Co-antioxidant for α-Tocopherol, Inhibiting Human Low Density Lipoprotein and Plasma Lipid Peroxidation* , 1996, The Journal of Biological Chemistry.
[103] R. Burke,et al. Apoptotic neuron death in rat substantia nigra induced by striatal excitotoxic injury is developmentally dependent , 1996, Neuroscience Letters.
[104] H. Saito,et al. 3-Hydroxykynurenine toxicity on the rat striatum in vivo. , 1996, Japanese journal of pharmacology.
[105] S. Samarasinghe,et al. Distribution of the N-methyl-d-aspartate glutamate receptor subunit NR2A in control and amyotrophic lateral sclerosis spinal cord , 1996, Brain Research.
[106] C. Colton,et al. Species differences in the generation of reactive oxygen species by microglia , 1996, Molecular and chemical neuropathology.
[107] P. Ricciardi-Castagnoli,et al. Regulation of the Kynurenine Metabolic Pathway by Interferon‐γ in Murine Cloned Macrophages and Microglial Cells , 1996, Journal of neurochemistry.
[108] E. Major,et al. Human microglia convert l-tryptophan into the neurotoxin quinolinic acid. , 1992, The Biochemical journal.
[109] K. Goda,et al. Quinolinic Acid and Active Oxygens , 1996 .
[110] M. Heyes. The Kynurenine Pathway and Neurologic Disease , 1996 .
[111] G. Melillo,et al. Immunobiology of picolinic acid. , 1996, Advances in experimental medicine and biology.
[112] M. Heyes. The kynurenine pathway and neurologic disease. Therapeutic strategies. , 1996, Advances in experimental medicine and biology.
[113] K. Goda,et al. Quinolinic acid and active oxygens. Possible contribution of active Oxygens during cell death in the brain. , 1996, Advances in experimental medicine and biology.
[114] G. Curzon. Brain tryptophan. Normal and disturbed control. , 1996, Advances in experimental medicine and biology.
[115] N. Botting. Chemistry and neurochemistry of the kynurenine pathway of tryptophan metabolism , 1996 .
[116] J Kerby,et al. Pharmacological properties of recombinant human N-methyl-D-aspartate receptors comprising NR1a/NR2A and NR1a/NR2B subunit assemblies expressed in permanently transfected mouse fibroblast cells. , 1995, Molecular pharmacology.
[117] M. Rosenblum,et al. AIDS dementia complex and HIV‐1 brain infection: Clinical‐virological correlations , 1995, Annals of neurology.
[118] R. Banati,et al. Antibodies against microglia/brain macrophages in the cerebrospinal fluid of a patient with acute amyotrophic lateral sclerosis and presenile dementia. , 1995, Clinical Neuropathology.
[119] G. Kreutzberg,et al. Microglia, the first line of defence in brain pathologies. , 1995, Arzneimittel-Forschung.
[120] J. Rothstein. Excitotoxicity and neurodegeneration in amyotrophic lateral sclerosis. , 1995, Clinical neuroscience.
[121] B. Brew,et al. Neurocytotoxity of quinolinic acid in human brain cultures. , 1995, Journal of neurovirology.
[122] R. Burke,et al. Apoptosis in substantia nigra following developmental striatal excitotoxic injury. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[123] K. Kristensson,et al. Co-induction of neuronal interferon-gamma and nitric oxide synthase in rat motor neurons after axotomy: a role in nerve repair or death? , 1994, Journal of neurocytology.
[124] J. Haines,et al. Linkage of recessive familial amyotrophic lateral sclerosis to chromosome 2q33–q35 , 1994, Nature Genetics.
[125] R. Stocker,et al. Nitric oxide inhibits indoleamine 2,3-dioxygenase activity in interferon-gamma primed mononuclear phagocytes. , 1994, The Journal of biological chemistry.
[126] D. Longo,et al. Interleukin-4 inhibits indoleamine 2,3-dioxygenase expression in human monocytes. , 1994, Blood.
[127] D. Troost,et al. Neuronophagia in the motor cortex in amyotrophic lateral sclerosis , 1993, Neuropathology and applied neurobiology.
[128] T. Stone,et al. Neuropharmacology of quinolinic and kynurenic acids. , 1993, Pharmacological reviews.
[129] A. Schurr,et al. Quinolinate potentiates the neurotoxicity of excitatory amino acids in hypoxic neuronal tissue in vitro , 1993, Brain Research.
[130] M. Heyes. Metabolism and neuropathologic significance of quinolinic acid and kynurenic acid. , 1993, Biochemical Society transactions.
[131] P. Sindou,et al. Cell culture evidence for neuronal degeneration in amyotrophic lateral sclerosis being linked to glutamate AMPA/kainate receptors , 1993, The Lancet.
[132] M. Demitrack,et al. Quinolinic acid and kynurenine pathway metabolism in inflammatory and non-inflammatory neurological disease. , 1992, Brain : a journal of neurology.
[133] P. Mcgeer,et al. Immunologic reactions in amyotrophic lateral sclerosis brain and spinal cord tissue. , 1992, The American journal of pathology.
[134] S. Markey,et al. Human macrophages convert L-tryptophan into the neurotoxin quinolinic acid. , 1992, The Biochemical journal.
[135] G. Martin,et al. Glutamine synthesis from aspartate in guinea-pig renal cortex. , 1990, The Biochemical journal.
[136] K. Kristensson,et al. Gamma-interferon-like immunoreactivity in axotomized rat motor neurons , 1989, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[137] T. Guilarte,et al. Cytotoxicity of 3-hydroxykynurenine in a neuronal hybrid cell line , 1989, Brain Research.
[138] R. Beninger,et al. Kynurenic acid protects against the neurochemical and behavioral effects of unilateral quinolinic acid injections into the nucleus basalis of rats. , 1989, Behavioral neuroscience.
[139] R. Schwarcz,et al. Kynurenic acid blocks neurotoxicity and seizures induced in rats by the related brain metabolite quinolinic acid , 1984, Neuroscience Letters.
[140] R. Schwarcz,et al. Quinolinic acid: an endogenous metabolite that produces axon-sparing lesions in rat brain. , 1983, Science.
[141] D. Bender,et al. The preferred route of kynurenine metabolism in the rat. , 1982, Biochimica et biophysica acta.
[142] T. Stone,et al. Quinolinic acid: a potent endogenous excitant at amino acid receptors in CNS. , 1981, European journal of pharmacology.